A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients

Published:2021-06-19 Issue: Volume: Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Stodtmann Sven¹,Nuthalapati Silpa²,Eckert Doerthe¹,Kasichayanula Sreeneeranj²,Joshi Rujuta²,Bach Bruce A.³,Mensing Sven¹,Menon Rajeev²,Xiong Hao²

Affiliation:

1. Clinical Pharmacology and Pharmacometrics AbbVie Deutschland GmbH & Co. KG Ludwigshafen am Rhein Germany

2. Clinical Pharmacology and Pharmacometrics AbbVie Inc North Chicago Illinois USA

3. Oncology Development AbbVie Inc North Chicago Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1875

Reference19 articles.

1. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

2. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

3. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

4. A phase I study of chronically dosed, single‐agent veliparib (ABT‐888) in patients (pts) with either BRCA 1/2‐mutated cancer (BRCA+), platinum‐refractory ovarian cancer, or basal‐like breast cancer (BRCA‐wt);Huggins‐Puhalla SL;J Clin Oncol,2012

5. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Veliparib exerts protective effects in intracerebral hemorrhage mice by inhibiting the inflammatory response and accelerating hematoma resolution;Brain Research;2024-09

2. Differential impact of cytoplasmic vs. nuclear RAD51 expression on breast cancer progression and patient prognosis;International Journal of Oncology;2023-12-07

3. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics;Seminars in Oncology;2023-10

4. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability;Journal of Medicinal Chemistry;2023-03-24

5. Transporter‑mediated drug‑drug interactions involving poly (ADP‑ribose) polymerase inhibitors (Review);Oncology Letters;2023-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3